Relief Hldg Stock Price, News & Analysis

RELIEF THERAPEUTICS Holding SA (OTCQB: RLFTF), historically referred to as Relief Therapeutics, is a commercial-stage biopharmaceutical company focused on rare and debilitating diseases. According to company disclosures, Relief concentrates on select specialty, unmet and rare conditions, with particular emphasis on dermatological, metabolic, and respiratory diseases. The company has highlighted drug delivery systems and drug repurposing as core areas of expertise and has brought several approved products to market through licensing and distribution partnerships.

Relief Therapeutics is headquartered in Geneva, Switzerland and its shares have been listed on the SIX Swiss Exchange under the symbol RLF, while also being quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. The company operates in the biopharmaceutical space within the broader manufacturing sector, with activities that span clinical development, regulatory engagement, and commercialization of therapies addressing high unmet medical needs.

Business focus and therapeutic areas

Company communications describe Relief as dedicated to advancing treatment paradigms for rare and debilitating diseases. Its clinical pipeline is said to include treatments targeting rare dermatological conditions, metabolic disorders, and respiratory diseases. Within this framework, Relief has reported work on:

• RLF-TD011, a highly pure, stabilized hypochlorous acid solution developed with the company’s TEHCLO™ technology, intended for wound care in epidermolysis bullosa (EB), a group of rare, inherited skin disorders characterized by extreme skin fragility and chronic wounds.
• RLF-OD032, an oral, highly concentrated liquid formulation of sapropterin dihydrochloride for the treatment of phenylketonuria (PKU), a genetic metabolic disorder caused by an inability to properly metabolize phenylalanine.

RLF-TD011 has been described as a sprayable, self-administered solution for targeted wound application, aimed at controlling infection and inflammation while reducing antibiotic use and easing intensive wound care routines. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease designations for RLF-TD011 in EB, and Relief has reported prior clinical experience with its acid-oxidizing solution in non-EB wounds.

For RLF-OD032, Relief has reported positive results from a pivotal bioequivalence clinical study demonstrating bioequivalence to KUVAN® Powder, a reference sapropterin product, under fed conditions. The company characterizes RLF-OD032 as a ready-to-use, portable, highly concentrated liquid that can be administered without water, with the goal of reducing dose volume and potentially improving treatment adherence for individuals living with PKU.

Regulatory interactions and designations

Relief has publicly discussed multiple regulatory interactions related to its pipeline. For RLF-TD011 in EB, the company has noted:

• Receipt of Orphan Drug Designation from the FDA.
• Receipt of Rare Pediatric Disease (RPD) designation from the FDA.
• A constructive pre-Investigational New Drug (pre-IND) meeting with the FDA to clarify remaining clinical and regulatory steps for later-stage development.
• A determination by the FDA that an initial request for Qualified Infectious Disease Product (QIDP) designation for RLF-TD011 did not meet QIDP criteria, with the company stating that this outcome does not change its development and regulatory strategy for the program.

For RLF-OD032 in PKU, Relief has reported that the pivotal bioequivalence study achieved its primary pharmacokinetic endpoints and that the investigational product was well tolerated, with no serious adverse events reported in the analysis described.

Corporate developments and transformation into MindMaze Therapeutics

In 2025, Relief Therapeutics announced a series of corporate steps leading to a business combination with NeuroX Group SA, a Swiss-based commercial-stage company that had acquired the assets and operations of the legacy MindMaze group. MindMaze had developed digital neurotherapeutics for neurological diseases and brain disorders, delivered via a brain technology platform integrating software, sensors, and telehealth.

According to company announcements, Relief and NeuroX entered into a binding term sheet for a proposed business combination intended to create a publicly listed, AI-based therapeutics platform. Shareholders of Relief subsequently approved resolutions at an extraordinary general meeting authorizing the combination and related capital measures, and the company indicated that it would be renamed MindMaze Therapeutics Holding SA upon completion of the transaction.

Later communications state that the business combination was completed in December 2025, forming MindMaze Therapeutics Holding SA, described as a Swiss-based, commercial-stage company. This combined entity is said to develop and commercialize digital treatments for neurological diseases and brain disorders based on an advanced brain technology platform. It is also reported to manage Relief’s preexisting portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.

Following completion of the transaction, the company has been described as listed on the SIX Swiss Exchange under the ticker MMTX and quoted in the U.S. on OTCQB under RLFTF and RLFTY. These disclosures indicate that the RLFTF symbol is associated with the combined entity operating as MindMaze Therapeutics Holding SA, while preserving Relief’s historical biopharmaceutical activities within the broader platform.

Position within the healthcare and therapeutics landscape

Based on the company’s own descriptions, Relief Therapeutics’ historical role centers on rare disease biopharmaceutical development, with particular focus on:

• Rare dermatological conditions, including epidermolysis bullosa.
• Metabolic disorders such as phenylketonuria.
• Select respiratory diseases.

With the formation of MindMaze Therapeutics Holding SA through the business combination with NeuroX, the corporate scope described in public communications extends to digital neurotherapeutics and an AI-powered brain health platform, while continuing to manage Relief’s biopharmaceutical asset portfolio. Investors researching RLFTF therefore encounter both the historical Relief Therapeutics biopharmaceutical profile and the newer, combined MindMaze Therapeutics structure as outlined in the company’s press releases.

Frequently asked questions about Relief Therapeutics and RLFTF